Horizon’s CEO, Tim Walbert, will reportedly get around $135 million when the company is sold to Amgen. He has mastered a particular kind of industry expertise: taking drugs invented and tested by other people, wrapping them expertly in hard-nosed marketing and warm-hued patient relations, raising their prices, and enjoying astounding revenues without spending one dime on drug development.